FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2134035552> ?p ?o ?g. }

• W2134035552 endingPage "314" @default.
• W2134035552 startingPage "306" @default.
• W2134035552 abstract "Since the receptor for advanced glycation end products (RAGE)-ligand axis has been demonstrated to be important in fibrogenesis, rat models may be used to assess whether specific small interfering RNAs (siRNAs) that target RAGE are able to reduce the progression of hepatic fibrosis. However, the effect of RAGE-targeted siRNA on established hepatic fibrosis remains to be elucidated. In the present study, RAGE-specific siRNA expression vectors were constructed prior to the animal experiment. Sprague-Dawley rats were treated initially with olive oil (2 ml/kg) or 50% CCl4 (2 ml/kg; CCl4/olive oil=1:1) twice per week for six weeks to generate the fibrosis model. The rats were then treated with phosphate‑buffered saline, a RAGE-specific siRNA expression vector, at different doses or a non-specific siRNA expression vector twice weekly via tail vein injection for up to six weeks, and were sacrificed at week two, four or six. Compared with the control groups, RAGE‑specific siRNA therapy significantly decreased RAGE mRNA and protein expression in rat livers (P<0.01). Following six weeks of RAGE gene-silencing treatment, the liver function, which was assessed by analyzing serum levels of alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP) and total bilirubin (TBIL), improved to varying degrees (P<0.01). The expression of nuclear factor-κB (NF-κB) significantly decreased following RAGE gene‑silencing therapy (P<0.01). In addition, the serum levels of inflammatory cytokines, including tumor necrosis factor‑α (TNF-α) and interleukin-6 (IL-6), and extracellular matrix (ECM) components, including hyaluronic acid (HA), laminin (LN) and procollagen type III (PCIII) also decreased (P<0.01). Furthermore, the expression of α-smooth muscle actin (α-SMA) and collagen I, which indicate the activation of hepatic stellate cells (HSCs), were downregulated following RAGE gene-silencing therapy (P<0.01). Furthermore, the inflammatory activity grade and fibrosis stage of rat livers also significantly improved compared with the control groups following RAGE gene-silencing therapy. Specific targeting of RAGE using siRNA may inhibit RAGE gene expression effectively in the rat hepatic fibrosis model and attenuate the progression of established hepatic fibrosis. This therapeutic effect may be mediated via inhibition of the expression of NF-κB. These findings suggest that RAGE may be a new target to prevent hepatic fibrosis." @default.
• W2134035552 created "2016-06-24" @default.
• W2134035552 creator A5005826313 @default.
• W2134035552 creator A5032062559 @default.
• W2134035552 creator A5035535543 @default.
• W2134035552 creator A5056656494 @default.
• W2134035552 creator A5059913267 @default.
• W2134035552 creator A5080125836 @default.
• W2134035552 creator A5083170334 @default.
• W2134035552 date "2014-05-02" @default.
• W2134035552 modified "2023-10-16" @default.
• W2134035552 title "Anti-fibrotic effects of specific-siRNA targeting of the receptor for advanced glycation end products in a rat model of experimental hepatic fibrosis" @default.
• W2134035552 cites W1503258737 @default.
• W2134035552 cites W1594856996 @default.
• W2134035552 cites W1965175217 @default.
• W2134035552 cites W1973433561 @default.
• W2134035552 cites W1977168314 @default.
• W2134035552 cites W1979599736 @default.
• W2134035552 cites W1981900811 @default.
• W2134035552 cites W1984830754 @default.
• W2134035552 cites W1985403454 @default.
• W2134035552 cites W2003043352 @default.
• W2134035552 cites W2024880904 @default.
• W2134035552 cites W2032395503 @default.
• W2134035552 cites W2035280748 @default.
• W2134035552 cites W2046392507 @default.
• W2134035552 cites W2081490773 @default.
• W2134035552 cites W2084559469 @default.
• W2134035552 cites W2088071075 @default.
• W2134035552 cites W20888715 @default.
• W2134035552 cites W2089149502 @default.
• W2134035552 cites W2104938297 @default.
• W2134035552 cites W2105482874 @default.
• W2134035552 cites W2105896882 @default.
• W2134035552 cites W2116491857 @default.
• W2134035552 cites W2118170059 @default.
• W2134035552 cites W2121527030 @default.
• W2134035552 cites W2134845413 @default.
• W2134035552 cites W2163351331 @default.
• W2134035552 cites W2167158568 @default.
• W2134035552 cites W2470223656 @default.
• W2134035552 doi "https://doi.org/10.3892/mmr.2014.2207" @default.
• W2134035552 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/24804792" @default.
• W2134035552 hasPublicationYear "2014" @default.
• W2134035552 type Work @default.
• W2134035552 sameAs 2134035552 @default.
• W2134035552 citedByCount "17" @default.
• W2134035552 countsByYear W21340355522015 @default.
• W2134035552 countsByYear W21340355522016 @default.
• W2134035552 countsByYear W21340355522017 @default.
• W2134035552 countsByYear W21340355522018 @default.
• W2134035552 countsByYear W21340355522019 @default.
• W2134035552 countsByYear W21340355522020 @default.
• W2134035552 countsByYear W21340355522021 @default.
• W2134035552 countsByYear W21340355522022 @default.
• W2134035552 countsByYear W21340355522023 @default.
• W2134035552 crossrefType "journal-article" @default.
• W2134035552 hasAuthorship W2134035552A5005826313 @default.
• W2134035552 hasAuthorship W2134035552A5032062559 @default.
• W2134035552 hasAuthorship W2134035552A5035535543 @default.
• W2134035552 hasAuthorship W2134035552A5056656494 @default.
• W2134035552 hasAuthorship W2134035552A5059913267 @default.
• W2134035552 hasAuthorship W2134035552A5080125836 @default.
• W2134035552 hasAuthorship W2134035552A5083170334 @default.
• W2134035552 hasBestOaLocation W21340355521 @default.
• W2134035552 hasConcept C104317684 @default.
• W2134035552 hasConcept C119056186 @default.
• W2134035552 hasConcept C126322002 @default.
• W2134035552 hasConcept C134018914 @default.
• W2134035552 hasConcept C147990577 @default.
• W2134035552 hasConcept C169760540 @default.
• W2134035552 hasConcept C170493617 @default.
• W2134035552 hasConcept C17991360 @default.
• W2134035552 hasConcept C185592680 @default.
• W2134035552 hasConcept C22615655 @default.
• W2134035552 hasConcept C2778857457 @default.
• W2134035552 hasConcept C2780559512 @default.
• W2134035552 hasConcept C2993667909 @default.
• W2134035552 hasConcept C502942594 @default.
• W2134035552 hasConcept C55493867 @default.
• W2134035552 hasConcept C67705224 @default.
• W2134035552 hasConcept C71924100 @default.
• W2134035552 hasConcept C86803240 @default.
• W2134035552 hasConceptScore W2134035552C104317684 @default.
• W2134035552 hasConceptScore W2134035552C119056186 @default.
• W2134035552 hasConceptScore W2134035552C126322002 @default.
• W2134035552 hasConceptScore W2134035552C134018914 @default.
• W2134035552 hasConceptScore W2134035552C147990577 @default.
• W2134035552 hasConceptScore W2134035552C169760540 @default.
• W2134035552 hasConceptScore W2134035552C170493617 @default.
• W2134035552 hasConceptScore W2134035552C17991360 @default.
• W2134035552 hasConceptScore W2134035552C185592680 @default.
• W2134035552 hasConceptScore W2134035552C22615655 @default.
• W2134035552 hasConceptScore W2134035552C2778857457 @default.
• W2134035552 hasConceptScore W2134035552C2780559512 @default.
• W2134035552 hasConceptScore W2134035552C2993667909 @default.
• W2134035552 hasConceptScore W2134035552C502942594 @default.
• W2134035552 hasConceptScore W2134035552C55493867 @default.

• next